Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. - Wikidata - wikimedia - TriplyDB

Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

http://www.wikidata.org/entity/Q55041777

about

Treatment for Barrett's oesophagus Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants Molecular cancer prevention: Current status and future directions What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?Oral premalignancy: the roles of early detection and chemoprevention Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma.Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research Disruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acid Molecular changes in the multistage pathogenesis of head and neck cancer Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.Effects of cigarette smoke on the human oral mucosal transcriptome p53 modulates Hsp90 ATPase activity and regulates aryl hydrocarbon receptor signaling.A DNA methyltransferase inhibitor and all-trans retinoic acid reduce oral cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide.PPARγ in head and neck cancer prevention Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence Pooling prospective studies to investigate the etiology of second cancers.Association of alpha B-crystallin genotypes with oral cancer susceptibility, survival, and recurrence in Taiwan.Methylation-associated gene silencing of RARB in areca carcinogens induced mouse oral squamous cell carcinoma.Oral epithelial stem cells - implications in normal development and cancer metastasis.Second primary tumors in patients with head and neck cancer.High-throughput screening of saliva for early detection of oral cancer: a pilot study.Retinoic acid regulates cell cycle genes and accelerates normal mouse liver regeneration.Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers.Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.The effect of cigarette smoking on cancer treatment-related side effects.Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.Correlates of continued smoking versus cessation among survivors of smoking-related cancers.Competing causes of death in patients with oropharyngeal cancer treated with radiotherapy.No Ifs, No Butts: Compliance with Smoking Cessation in Secondary Care Guidance (NICE PH48) by Providers of Cancer Therapies (Radiotherapy and Chemotherapy) in the UK.Topical oral cavity chemoprophylaxis using isotretinoin rinse: A 15-year experience.Harm reduction and cessation efforts and interest in cessation resources among survivors of smoking-related cancers Retinoids and rexinoids in cancer prevention: from laboratory to clinic.Tumor-suppressive activity of retinoic acid receptor-beta in cancer.Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment

P2860

Q24240701-DD3E303A-E261-407C-941D-41B9566021D8 Q24624194-141CDDB3-9D08-4B36-9197-3E91846E0592 Q26797207-9B91E01C-D1C4-49C3-88EC-AD0267D2EBC9 Q27026269-2073C1C3-AD55-43F9-BD6C-2C6A67EEE9F0 Q27693327-B1E42ABF-89DD-4D85-BAAD-5CF8E7ABCB8C Q27853287-3C84F676-313C-4937-A081-EAB4596FA34D Q28085361-67CC5C18-8947-48AB-BC08-65B20D7484F4 Q28469292-D0CBB80B-F55D-4EA9-BF7E-7D3451CB178D Q28728638-D26728B8-01EA-473B-AD8F-8E5E11E8BA66 Q30498812-A84C4EED-1ACA-434D-B9F8-8BF4C7F0FDDE Q31001228-5D650B2F-AA41-4201-89ED-B6EF23D6D592 Q33707973-3D93777B-6CEF-4EF4-98B4-91C104D29402 Q33819326-DCE5DBB3-13C6-42BA-998A-C64B569FE276 Q33880963-7640A572-D6B2-462B-8C56-802851281CA8 Q33896090-173420B9-7488-40E3-B926-D68323BBF5C5 Q33922877-212A53DB-58D2-4EEA-9474-4A456616D781 Q33992357-A8A76312-8CF5-45EE-9054-924DE75587A9 Q34018837-7FA9B67D-51CA-4AA0-9648-7DADB6541C5C Q34114486-47C28F12-2140-4F20-A4EF-332E64E41B2C Q34147649-BDC1EC38-615A-4584-B816-47E4CA852209 Q34158978-BDFAFF12-DEB3-4AA9-87CA-496D2E2713A4 Q34159301-A1CC1BB0-5ED4-47AA-BDAA-31879CFBD63C Q34539985-98E5394B-2C32-4F5A-8E65-F15D2251D666 Q34611659-BF4F2CF4-D898-4FC7-86AF-B66FE75A6493 Q34646050-B2BC8360-2575-44F8-A899-C789D6ED6ED1 Q34790902-041A9647-A3F5-468A-B1B5-2E300640097E Q34953372-84F80B4B-82F4-4F33-B2A9-524876F2633F Q34977797-8FAEC5DE-A77D-41D8-9E65-EE1930E57D0C Q35642404-DAA69B75-CC47-43FA-8F91-A651EE4899F1 Q35839993-5C43279C-0C14-4862-A403-A67A0F72CF78 Q36097436-CF993947-B541-4D23-9B3C-DB8E403AA0BC Q36115675-148D9772-0185-49A9-BE02-DB472ADD7292 Q36183327-4B60D346-CEC7-4557-ADCA-119DBEC022F7 Q36224590-35FAFEB7-85B8-4E17-8D9A-F7F4A476E46A Q36226602-187F416C-A219-4660-97D3-3EC4918EBD31 Q36230020-39458F98-99F9-49D3-9477-DFD727DF07DE Q36597905-A219A9F6-CAA1-437F-A862-60F7F1ADCDEC Q36680198-44DF10D9-D928-4B80-88F4-4B4E72E18B03 Q36692169-9FEBD0D6-F9ED-4FFA-B7B7-A4B46CA4CA59 Q36745391-4144B627-3095-43B1-B5C5-70C4FAA4AD8A

P2860

Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

http://www.wikidata.org/entity/Q55041777

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Randomized phase III trial of ...... head and neck cancer patients.

@en

Randomized phase III trial of ...... head and neck cancer patients.

@nl

type

label

Randomized phase III trial of ...... head and neck cancer patients.

@en

Randomized phase III trial of ...... head and neck cancer patients.

@nl

prefLabel

Randomized phase III trial of ...... head and neck cancer patients.

@en

Randomized phase III trial of ...... head and neck cancer patients.

@nl

P1433

Q55041777-FCAA1721-C94F-4E58-B393-6449BBC513FC

P1476

Q55041777-731C10F2-9E71-4E27-9726-1457F84228F0

P2093

Q55041777-0BD48E64-8F36-4D79-9374-8F067715C5CF

Q55041777-0F450F27-AF7B-4612-AEED-4795A49405C9

Q55041777-25835288-FFDA-4748-89DE-747A550D8046

Q55041777-43A6617B-C890-424B-82AC-F7FE931429AC

Q55041777-52B055B3-7834-4227-A342-09EA51CC5B33

Q55041777-5519E351-9675-4B9A-B8D1-A282E6F4345E

Q55041777-5578626B-8884-4F70-B455-B1321BA03D5E

Q55041777-599121DE-CBA3-4611-85C4-8695B1DC9A57

Q55041777-5A1C6763-F76F-4E02-B99A-261728020DDB

Q55041777-66B8F94E-5B90-407B-B2A4-1BFDAD8C40CC

P2860

Q55041777-051FD665-022E-4C7D-8D13-39FCE1AE6416

Q55041777-0722FB65-28A6-47F2-AC8F-BFBDA5C563E7

Q55041777-0D686D24-1618-485F-9D44-391BEA0A01BE

Q55041777-2F14ECC0-18B4-4682-B6CF-8B7C8D511AA9

Q55041777-320EF46B-76E5-4ACC-8B9C-AA70C27F92B5

Q55041777-3536B24E-6DE6-47AC-B749-F437E21C6E43

Q55041777-3F362793-D03F-4DE0-9228-70E1DE8EAA29

Q55041777-41FDCE8C-1016-4014-BF65-61D0CD76C92F

Q55041777-45792509-75FD-49AA-81DB-665CEBC9D2BF

Q55041777-58166239-E3F8-408E-AA24-CFCE18CC5EAB

P304

Q55041777-8059306E-77F4-4C10-8526-BBDDA1B16200

P31

Q55041777-FCE91C16-1D56-4412-912F-234B9093BB8B

P356

Q55041777-D1463363-54FD-4E0C-8D7A-FEED1217A245

P407

Q55041777-E09B825B-EFF1-4FD9-97E7-CD74D011550B

P433

Q55041777-1EBCAF6B-5CD3-40D6-82B9-75BCF1A14220

P478

Q55041777-F73A10CD-883A-49D5-A75A-6549659B2E32

P50

Q55041777-9DD83E74-6C6F-425B-A18D-7057714BEDDF

P577

Q55041777-A0A74A4F-9CF5-4F03-8CD2-83C419C6CCAE

P5875

Q55041777-197BA83C-A74E-4CC4-AD8A-624648B4D431

P698

Q55041777-11819884-F52A-4490-B816-D5DCC81EABB1

P921

Q55041777-4E30D7D4-2BF3-49B7-8010-ADD700DAE5B4

P356

P1433

Journal of the National Cancer Institute

P1476

Randomized phase III trial of ...... head and neck cancer patients.

@en

P2093

Brendell Williams

http://www.w3.org/2001/XMLSchema#string

Dong M Shin

http://www.w3.org/2001/XMLSchema#string

Edward S Kim

http://www.w3.org/2001/XMLSchema#string

Fadlo R Khuri

http://www.w3.org/2001/XMLSchema#string

George Shenouda

http://www.w3.org/2001/XMLSchema#string

Helmuth Goepfert

http://www.w3.org/2001/XMLSchema#string

Ian Hodson

http://www.w3.org/2001/XMLSchema#string

J Jack Lee

http://www.w3.org/2001/XMLSchema#string

Jay S Cooper

http://www.w3.org/2001/XMLSchema#string

Karen Fu

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Cancer statistics, 2005

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

13-cis-retinoic acid in the treatment of oral leukoplakia.

Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract.

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.

Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.

Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers.

Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.

P304

441-450

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJJ091

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

Everett E Vokes

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7183651

http://www.w3.org/2001/XMLSchema#string

P698

16595780

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial